10-Q 1 rgbp063019form10q.htm FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-191725

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	45-5192997
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

619 702 1404

(Issuer’s telephone number)

None

(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☐ Non-accelerated filer	☒ Smaller reporting company

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of August 26, 2019 there were 571,484,406 shares of common stock issued and outstanding.

As of August 26, 2019 there were 348,220,210 shares of Series A Preferred Stock issued and outstanding.

As of August 26, 2019 there were 38,000,000 shares of Series M Preferred Stock issued and outstanding

As of August 26, 2019 there were 50,000 shares of Series AA Preferred Stock issued and outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

REGEN BIOPHARMA , INC.
CONSOLIDATED CONDENSED BALANCE SHEETS

	As of			As of
	June 30, 2019 (unaudited)			September 30, 2018
ASSETS
CURRENT ASSETS
Cash	$	1,812		$	8,019
Accounts Receivable, Related Party		43,460			0
Note Receivable, Related Party					4,551
Note Receivable					0
Prepaid Expenses		89			8,259
Accrued Interest Receivable					7,672
Prepaid Rent					14,270
Total Current Assets		45,361			42,771
OTHER ASSETS
Investment Securities		68,943			166,247
Total Other Assets		68,943			166,247
TOTAL ASSETS		114,304		$	209,018

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Bank Overdraft		266		$	203
Accounts payable		94,548			80,567
Notes Payable		62,740			227
Accrued payroll taxes		4,241			4,241
Accrued Interest		448,478			292,094
Accrued Rent					0
Accrued Payroll		886,658			655,663
Other Accrued Expenses		41,423			41,243
Due to Investor		20,000			20,000
Derivative Liability		9,482,064			6,736,607
Convertible Notes Payable Less unamortized discount		1,327,301			774,666
Unearned Income					68,000
Total Current Liabilities		12,367,719			8,673,511
Long Term Liabilities:
Convertible Notes Payable less unamortized discount		528,647			656,272
Convertible Notes Payable, Related Parties Less unamortized discount		4,025			906
Total Long Term Liabilities		532,672			657,178
Total Liabilities		12,900,392			9,330,689

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 180,315,107 issued and outstanding as of September 30, 2018 and 1,800,000,000 authorized and 518,452,006 shares issued and outstanding June 30, 2019		51,843			18,030
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of June 30, 2019 and September 30, 2018 respectively
Series A Preferred; 300,000,000 authorized, 140,434,496 and 348,376,230 outstanding as of September 30, 2018 and June 30, 2019		34,838			14,044
Series AA Preferred; $0.0001 par value 600,000 authorized and 50, 000 and 50,000 outstanding as of June 30, 2019 and September 30, 2018, respectively		5
Series M Preferred; $0.0001 par value 300,000,000 authorized and and 38,000,000 outstanding as of September 30, 2018 and June 30, 2019 respectively		3,800			3,800
Additional Paid in capital		8,240,724			7,517,888
Contributed Capital		728,658			728,658
Retained Earnings (Deficit)		(21,861,598	)		(17,457,044	)
Accumulated Other Comprehensive Income		0			52,948
Shareholders Equity Regen Biopharma		(12,801,730	)		(9,121,671	)
Non Controlling Interest KCL Therapeutics		15,642			0
Total Stockholders' Equity (Deficit)		(12,786,088	)		(9,121,671	)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	114,304		$	209,018

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA , INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(unaudited)

	Quarter Ended						Nine Months Ended
	June 30, 2019			June 30, 2018			June 30, 2019			June 30, 2018
REVENUES
Revenues, Related Party	$	27,425		$	100,000		$	82,274		$	100,000

COST AND EXPENSES
Research and Development		15,328			10,355			23,268			340,388
General and Administrative		111,292			172,626			396,708			570,867
Consulting and Professional Fees		23,525			27,253			184,645			306,236
Rent		15,000			15,000			45,000			45,000
Total Costs and Expenses		165,145			225,234			649,621			1,262,491

OPERATING INCOME (LOSS)		(137,720	)		(125,234	)		(567,347	)		(1,162,491	)

OTHER INCOME & (EXPENSES)
Interest Income		0			577			1,302			10,121
Other Income					96						96
Dividend Income					5,741						5,741
Loss on Sale of Securities		0						(57,697	)
Unrealized Gain(Loss) Investment Securities		56,277						(2,870	)
Interest Expense		(70,685	)		(63,618	)		(209,110	)		(194,093	)
Refunds of amounts previously paid		0						115
Interest Expense attributable to
Amortization of Discount		(482,036	)		(337,060	)		(1,160,136	)		(989,096	)
Gain (Loss) on Early Extinguishment Convertible Debt		33,567			(62,300	)		33,567			(103,866	)
Bad Debt Expense								(118,121	)
Derivative Income (Expense)		(3,804,486	)		474,202			(2,406,391	)		(1,300,011	)
TOTAL OTHER INCOME (EXPENSE)		(4,267,362	)		17,638			(3,919,339	)		(2,571,107	)

NET INCOME (LOSS)	$	(4,405,083	)	$	(107,596	)	$	(4,486,687	)	$	(3,733,598	)
Less:Net (Income) Loss attributable to KCL, Therapeutics, Inc.		(4,791	)					(7,291	)
NET INCOME (LOSS) attributable to common shareholders		(4,409,874	)		(107,596	)		(4,493,978	)		(3,733,598	)

BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	($	0.0514	)	($	0.0007	)	($	0.0136	)	($	0.0252	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		85,870,761			153,505,198			330,314,986			148,379,644

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA, INC.

Condensed Consolidated Statement of Shareholder’s Deficit

Nine Months Ended June 30, 2018

(unaudited)

	Series A Preferred				Series AA Preferred				Common				Series M Preferred
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital		Retained Earnings			Contributed Capital		Other Comprehensive Income (Loss)					Total
Balance September 30, 2017		136,966,697	$	13,697		50,000	$	5		139,704,157	$	13,969		32,000,000	$	3,200	$	6,642,979	$	(12,741,843	)	$	728,658	$	88,000		$	0	$	(5,251,335	)
Common Shares issued to Consultant 10/9/2017										2,500,000		250						109,500												109,750
Preferred Shares issued to Consultant 10/11/2017														2,000,000		200														200
Preferred Shares issued to Consultant 11/01/2017														4,000,000		400														400
Common Shares issued for Debt 12/6/2017										3,976,852		398						85,502												85,900
Unrealized Gain on Securities Available for Sale recognized during Quarter ended December 31, 2017																									40,000					40,000
Net Loss for the quarter ended December 31, 2017																				(2,785,149	)									(2,785,149	)
Balance December 31 , 2017		136,966,697		13,697		50,000		5		146,181,009		14,617		38,000,000		3,800		6,837,981		(15,526,990	)		728,658		128,000			0		(7,800,232	)
Common Shares issued for Debt 1/10/2018										332,955		33						10,376												10,409
Preferred Shares Purchased for Cash 1/29/2018		2,500,000		250														24,750												25,000
Common Shares Purchased for Cash 1/29/2018										2,500,000		250						24,750												25,000
Common Shares issued for Debt 2/6/2018										522,255		52						13,560												13,612
Common Shares issued for Debt 3/6/2018										796,254		80						18,862												18,942
Common Shares issued to Consultant 3/15/2018										250,000		25						7,900												7,925
Common Shares issued for Debt 3/27/2018										744,948		74						12,613												12,687
Unrealized Loss on Securities Available for Sale recognized during Quarter ended March 31, 2018																									(19,200	)				(19,200	)
Net Loss for the quarter ended March 31, 2018																				(840,851	)									(840,851	)
Balance March 31, 2018		139,466,697		13,947	$	50,000		5		151,327,421	$	15,131		38,000,000	$	3,800	$	6,950,792	$	(16,367,844	)	$	728,658	$	108,800		$	0		(8,546,711	)
Preferred Shares issued for Debt 4/10/2018		40,080		4														1,038												1,042
Common Shares issued for Debt 4/20/2018										785,237		79						12,681												12,760
Common Shares issued for Debt 4/30/2018										363,597		36						5,163												5,199
Common Shares issued for Debt 5/7/2018										403,583		40						5,206												5,246
Preferred Shares issued for Debt 5/18/2018		108,004		11														2,095												2,106
Preferred Shares issued for Debt 6/1/2018		146,407		15														2,097												2,112
										405,858		41						5,235												5,276
Common Shares issued for Debt 6/11/2018										728,390		73						10,674												10,747
Preferred Shares issued for Debt 6/13/2018		181,018		18														2,099												2,117
Common Shares issued for Debt 6/15/2018										4,712,320		471						58,433												58,904
Unrealized Loss on Securities Available for Sale recognized during Quarter ended June 30, 2018																									(18,400	)				(18,400	)
Net Loss for the quarter ended June 30, 2018																				(107,596	)									(107,596	)
Balance June 30, 2018		139,942,206		13,994		50,000		5		158,726,406		15,871		38,000,000		3,800		7,055,513		(16,475,440	)		728,658		90,400					(8,567,198	)

The accompanying Notes are an integral part of these Financial Statements

REGEN BIOPHARMA, INC.

Condensed Consolidated Statement of Shareholder’s Deficit

Nine Months Ended June 30, 2019

(unaudited)

	Series A Preferred				Series AA Preferred				Common				Series M Preferred
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital			Retained Earnings			Contributed Capital		Accumulated Other Comprehensive Income (Loss)			Noncontrolling Interest		Total
Balance September 30, 2018		140,434,496	$	14,044		50,000	$	5		180,315,107	$	18,030		38,000,000	$	3,800	$	7,517,888		$	(17,457,044	)	$	728,658	$	52,948		$	0	$	(9,121,670)
10/1/2018; 5,128,205 shares issued for debt										5,128,205		513						29,487													30,000
10/18/2018; 8,961,988 shares issued for debt										8,961,988		896						29,754													30,650
10/23/2018; 2,019,140 shares issued for debt										2,019,140		202						7,410													7,612
10/29/2018; 3,015,618 shares issued for debt										3,015,618		302						11,066													11,368
11/15/2018; 7,100,591 shares issued for debt										7,100,591		710						29,290													30,000
11/20/2018; 3,656,020 shares issued for debt		3,656,020		366														5,099													5,465
11/28/2018; 9,198,923 shares issued for debt										29,033,181		2,903						47,813													50,716
11/28/2018; 286,232 shares issued for expenses										286,232		29						471													500
12/19/2018; 5,184,674 shares issued for debt										5,184,674		518						9,929													10,447
12/26/2018; 617,283 shares issued for expenses										617,283		62						438													500
12/26/2018; 10,382,717 shares issued for debt										10,382,717		1,038						7,372													8,410
12/31/2018; Derecognition of Accumulated Other Comprehensive Income																					52,948					(52,948	)				0
12/31/2019; Adjustment for Adoption ASU 2014 -09																					29,186										29,186
12/31/2018; Net Income for the Quarter Ended December 31, 2019																					249,986										249,986
Balance 12/31/2018		144,090,516	$	14,409		50,000	$	5		252,044,737	$	25,203		38,000,000	$	3,800	$	7,696,017		$	(17,124,924	)	$	728,658	$	0		$	0	$	(8,656,832	)
1/3/2019;10,585,123 shares issued for debt										10,585,123		1,059						12,692													13,751
1/9/2019; 10,000,000 shares issued for services		10,000,000		1,000														48,000													49,000
1/23/2019; 5,774,947 shares issued for debt										5,774,947		577						6,555													7,132
1/25/2019; 877,310 shares issued for expenses										877,310		88						412													500
1/25/2019; 12,222,690 shares issued for debt										12,222,690		1,222						5,744													6,966
2/11/2019; 10,473,668 shares issued for debt										10,473,668		1,047						11,887													12,934
2/13/2019; Shares of subsidiary issued for services																		441													441
2/15/2019; 13,821,193 shares issued for debt										13,821,193		1,382						14,374													15,756
2/19/2019; 13,790,783 shares issued for debt										13,790,783		1,379						18,341													19,720
3/1/2019; 8,004,463 shares issued for debt										8,004,463		800						7,844													8,644
3/4/2019; 694,508 shares issued for expenses										694,508		69						431													500
3/4/2019; 14,305,492 shares issued for debt										14,305,492		1,431						8,868													10,299
3/19/2019; 833,449 shares issued for expenses										833,449		83						417													500
3/19/2019; 27,377,166 shares issued for debt										27,377,166		2,738						19,766													22,504
3/22/2019; 6,309,524 shares issued for debt										6,309,524		631						4,669													5,300
3/31/2019; Adjustment for noncontrolling Interest KCL Therapeutics, Inc.																		(2,934	)										2,934		0
3/31/2019; Net Loss for Quarter Ended March 31 2019																					(331,590	)									(331,590	)
Balance March 31 2019		154,090,516	$	15,409		50,000	$	5		377,115,053	$	37,710		38,000,000	$	3,800	$	7,853,523		$	(17,456,515	)	$	728,658	$	0		$	2,934	$	(8,814,475	)
4/1/2019; 895,116 shares issued for debt										8,958,116		896						3,403													4,299
4/1/2019; 1,041,884 shares issued for expenses										1,041,884		104						396													500
4/2/2019; 12,992,389 shares issued for debt										12,992,389		1,299						8,055													9,354
4/8/2019; 17,971,064 shares issued for debt										17,971,064		1,797						12,220													14,017
4/9/2019; 11,832,569 shares issued for debt										11,832,569		1,183						7,336													8,519
4/11/2019; 19,472,820 shares issued for debt										19,472,820		1,947						13,241													15,188
4/18/2019; 14,824,958 shares issued for debt										14,824,958		1,482						9,191													10,673
4/29/2019; 22,243,153 shares issued for debt										22,243,153		2,224						15,125													17,349
4/30/2019; 895,116 shares issued for debt										8,958,116		896						3,403													4,299
4/30/2019; 1,041,884 shares issued for expenses										1,041,884		104						396													500
5/18/2019; 1,253,847 shares issued for expenses										1,253,847		125						375													500
5/18/2019; 20,746,153 shares issued for debt										20,746,153		2,075						6,198													8,273
6/27/2019; 104,285,714 shares issued for debt		194,285,714		19,429														320,571													340,000
6/30/2019; Adjustment for noncontrolling Interest KCL Therapeutics, Inc.																		(12,708	)										12,708
6/30/2019; Net Loss for Quarter ended June 30, 2019																					(4,405,083	)									(4,405,083	)
Balance June 30, 2019		348,376,230	$	34,838						518,452,006	$	51,843		38,000,000	$	3,800	$	8,240,724		$	(21,861,598	)	$	728,658	$	0		$	15,642	$	(12,786,088	)

The following Notes are an integral Part of these Condensed Financial Statements

REGEN BIOPHARMA , INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

	Nine Months Ended
	June 30, 2019			June 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$	(4,486,687	)	$	(3,733,598	)
Adjustments to reconcile net Income to net cash
Preferred Stock issued to Consultants		49,000			600
Common Stock issued to consultants					144,060
Common Stock issued for interest					5,888
Subsidiary Stock issued to consultants		46
Subsidiary Stock issued as compensation		294
Common Stock issued for Expenses		4,000
Increase (Decrease) in Interest expense attributable to
amortization of Discount		1,160,136			989,096
(Gain) Loss on Sale of Investment Securities		57,697
Increase(Decrease) in (Gain)/Loss on early extinguishment of debt		(33,567	)		103,866
Changes in operating assets and liabilities:
Unrealized (Gain) Loss on Investment Securities		2,870
Increase (Decrease) in Accounts Payable		13,977			(422,455	)
Increase (Decrease) Unearned Income		(38,814	)		68,000
(Increase) Decrease in Accounts Receivable		(43,460	)
Increase (Decrease) in accrued Expenses		428,585			417,250
(Increase) Decrease in Prepaid Expenses		13,271			(15,000	)
Increase in Derivative Expense		2,406,391			1,300,011
(Increase) Decrease in Interest Receivable		(1,303	)		(10,121	)
(Increase) Decrease in Notes Receivable		4,551			40,000
Increase(Decrease) in Bad Debt Expense		118,121
Increase(Decrease) in Bank Overdraft		63			203
Net Cash Provided by (Used in) Operating Activities		(344,829	)		(1,112,200	)

Cash Flows from Investment Activities
Increase(Decrease) in Sale of Investment Securities		49,858
Dividend Income					(5,741	)
Net Cash Provided By Investment Activities		49,858			(5,741	)

CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash		0			25,000
Preferred Stock issued for Cash		0			25,000
Increase ( Decrease) in Notes Payable		62,513			(108,128	)
Increase in Convertible Notes payable		226,250			950,000
Increase in Due to Investor					11,500
Net Cash Provided by (Used in) Financing Activities		288,763			903,372

Net Increase (Decrease) in Cash		(6,208	)		(214,569	)

Cash at Beginning of Period		8,019			269,973
Cash at End of Period	$	1,812		$	55,404

Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt		355,938			218,000
Preferred Shares Issued for Debt		345,000			7,000
Cash Paid for Interest		11,520			39,666
Common shares Issued for Interest		38,242			15,794
Preferred Shares issued for Interest					377

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of June 30, 2019

(Unaudited)

The accompanying unaudited interim condensed consolidated financial statements of Regen Biopharma , Inc. (“Regen” or “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the United States Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report filed with the SEC on Form 10-K for the year ended September 30, 2018. In general, interim disclosures do not repeat those contained in the annual statements. In the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease.

The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and majority owned subsidiary of Regen. Significant inter-company transactions have been eliminated. As of June 30, 2019 Regen owns 82.35% of KCL Therapeutics, Inc.

C. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

D. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

E. PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

F. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

G. DERIVATIVE LIABILITIES.

The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statement of operations.

The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.

The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of June 30, 2019 utilized the following inputs:

Risk Free Interest Rate	2.14	%
Expected Term	0.01 – 1.48 Yrs
Expected Volatility	188.87 – 273.20%
Expected Dividends	0

H. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2019 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended June 30, 2019 and 2018.

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

L. REVENUE RECOGNITION

Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products.

The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $21,861,598 during the period from April 24, 2012 (inception) through June 30, 2019. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the year ended September 30, 2018 the Company raised $50,000 through the sale of equity securities for cash, $1,382,750 through the sale of convertible notes, and $38,000 through the satisfaction of a Note Receivable issued as consideration for a convertible note issued by the Company. During the quarter ended December 31, 2018 the Company raised $131,250 through the issuance of convertible notes. During the quarter ended March 31, 2019 the Company raised $95,000 through the issuance of convertible notes

NOTE 4. NOTES PAYABLE , RELATED PARTY

	June 30, 2019
David Koos ( Note 7)		5,840
Zander Therapeutics, Inc. (Note 7)		56,900
Notes Payable, Related Parties	$	62,740

$5,840 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum

As of June 30, 2019 Regen Biopharma Inc. is indebted to ZanderTheraputics, Inc. (“Zander) in the amount of $56,900.

On January 10, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable January 10, 2020.

On January 14, 2019 Zander loaned $2,000 to Regen. The loan bears simple interest at 10% and is due and payable January 14, 2020.

On January 17, 2019 Zander loaned $1,500 to Regen. The loan bears simple interest at 10% and is due and payable January 17, 2020.

On April 11, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable April 11, 2020.

On April 30, 2019 Zander loaned $20,000 to Regen. The loan bears simple interest at 10% and is due and payable April 30, 2020.

On May 3, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable May 3, 2020.

On May 9, 2019 Zander loaned $400 to Regen. The loan bears simple interest at 10% and is due and payable May 9, 2020.

On May 29, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable May 29, 2020.

On May 31, 2019 Zander loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable May 31, 2020.

On June 6, 2019 Zander loaned $4,000 to Regen. The loan bears simple interest at 10% and is due and payable June 6, 2020.

On June 14, 2019 Zander loaned $3,000 to Regen. The loan bears simple interest at 10% and is due and payable June 14, 2020.

Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Caven also serve as a Director of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. All of Zander, Regen and KCL Therapeutics are agreeable that Zander shall be permitted at its option to apply any unpaid overdue liability of Regen ( including any and all accrued interest on promissory notes) towards any Anniversary fees and/or Minimum Royalties that may be payable by Zander pursuant to that license agreement originally entered into by Zander and Regen on June 23, 2015 ( Note 7).

NOTE 5. CONVERTIBLE NOTES PAYABLE

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:

(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities.

The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of June 30, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of June 30, 2019 $100,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of June 30, 2019 is $0.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of June 30, 2019 the unamortized discount on the convertible note outstanding is $0. As of June 30, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of June 30, 2019 is $0.

On September 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of June 30, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of June 30, 2019 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of June 30, 2019 is 0.

On September 20, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The amount by which the Note’s as converted value exceeds the principal amount as of June 30, 2019 is 0.

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of June 30, 2019 the unamortized discount on the convertible note outstanding is $0. As of June 30, 2019 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of June 30, 2019 is 0.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of June 30, 2019 the unamortized discount on the convertible note outstanding is $ 0 As of June 30, 2019 $50,000 of the principal amount of the Note remains outstanding.

The Lender shall have the right from time to time to convert all or a part of the outstanding and